{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-035074","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.409145+00:00","generated_at":"2026-06-06T02:43:48.461122+00:00","sec_items":["1.01","3.02","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"enGene raises $200M via oversubscribed private placement; CEO Hanson to resign for family/health reasons","bullets":["Sold 20M shares at $10.00 each (31% premium to Feb 13 close); gross proceeds $200M; expected close Feb 16.","New and existing investors participated, including Adage, Blue Owl, Boxer, Cormorant, Deerfield, and Janus Henderson.","Proceeds to fund EG-70 pivotal study for BCG-unresponsive NMIBC; cash runway extends into 2027.","CEO Jason Hanson to resign upon successor appointment due to personal family/health reasons; Board initiated search.","Hanson will serve as Senior Strategic Advisor for at least six months post-resignation at $25,000/month."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-035074","json":"https://secwatch.observer/filing/0001193125-24-035074.json","markdown":"https://secwatch.observer/filing/0001193125-24-035074.md","text":"https://secwatch.observer/filing/0001193125-24-035074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000119312524035074/0001193125-24-035074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000119312524035074/d772510d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:43:48.461122+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c97efcabb4","claim":"Jason Hanson departed as Chief Executive Officer at enGene Therapeutics Inc..","evidence_excerpt":"Mr. Hanson will resign from his positions as Chief Executive Officer of the Company and as a member of the Company’s Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000119312524035074/0001193125-24-035074-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resign"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"188ccd2d89cd87b364b717de1ac61b7f429f9636","claim":"enGene Therapeutics Inc. entered into Subscription Agreements with the investors named therein valued at approximately $200 million (effective 2024-02-13).","evidence_excerpt":"On February 13, 2024, enGene Holdings Inc. (the “ Company ”) entered into subscription agreements (collectively, the “ Subscription Agreements ”) with the investors named therein (the “ Investors ”), for the private placement (the “ Private Placement ”) of 20,000,000 common shares of the Company (the “ Subscribed Shares ”), at a price of $10.00 per share. The aggregate gross proceeds from the Private Placement are expected to be approximately $200 million, before deducting offering expenses.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000119312524035074/0001193125-24-035074-index.htm","confidence":0.96,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the investors named therein"},{"label":"Value","value":"approximately $200 million"},{"label":"Effective","value":"2024-02-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}